These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
267 related articles for article (PubMed ID: 26288094)
1. Guanabenz Treatment Accelerates Disease in a Mutant SOD1 Mouse Model of ALS. Vieira FG; Ping Q; Moreno AJ; Kidd JD; Thompson K; Jiang B; Lincecum JM; Wang MZ; De Zutter GS; Tassinari VR; Levine B; Hatzipetros T; Gill A; Perrin S PLoS One; 2015; 10(8):e0135570. PubMed ID: 26288094 [TBL] [Abstract][Full Text] [Related]
2. Guanabenz delays the onset of disease symptoms, extends lifespan, improves motor performance and attenuates motor neuron loss in the SOD1 G93A mouse model of amyotrophic lateral sclerosis. Jiang HQ; Ren M; Jiang HZ; Wang J; Zhang J; Yin X; Wang SY; Qi Y; Wang XD; Feng HL Neuroscience; 2014 Sep; 277():132-8. PubMed ID: 24699224 [TBL] [Abstract][Full Text] [Related]
3. Guanabenz, which enhances the unfolded protein response, ameliorates mutant SOD1-induced amyotrophic lateral sclerosis. Wang L; Popko B; Tixier E; Roos RP Neurobiol Dis; 2014 Nov; 71():317-24. PubMed ID: 25134731 [TBL] [Abstract][Full Text] [Related]
4. The UPR-PERK pathway is not a promising therapeutic target for mutant SOD1-induced ALS. Dzhashiashvili Y; Monckton CP; Shah HS; Kunjamma RB; Popko B Neurobiol Dis; 2019 Jul; 127():527-544. PubMed ID: 30923003 [TBL] [Abstract][Full Text] [Related]
5. Protein misfolding, amyotrophic lateral sclerosis and guanabenz: protocol for a phase II RCT with futility design (ProMISe trial). Bella ED; Tramacere I; Antonini G; Borghero G; Capasso M; Caponnetto C; Chiò A; Corbo M; Eleopra R; Filosto M; Giannini F; Granieri E; Bella V; Lunetta C; Mandrioli J; Mazzini L; Messina S; Monsurrò MR; Mora G; Riva N; Rizzi R; Siciliano G; Silani V; Simone I; Sorarù G; Volanti P; Lauria G BMJ Open; 2017 Aug; 7(8):e015434. PubMed ID: 28801400 [TBL] [Abstract][Full Text] [Related]
6. The unfolded protein response in models of human mutant G93A amyotrophic lateral sclerosis. Prell T; Lautenschläger J; Witte OW; Carri MT; Grosskreutz J Eur J Neurosci; 2012 Mar; 35(5):652-60. PubMed ID: 22390177 [TBL] [Abstract][Full Text] [Related]
7. Endoplasmic reticulum stress is accompanied by activation of NF-κB in amyotrophic lateral sclerosis. Prell T; Lautenschläger J; Weidemann L; Ruhmer J; Witte OW; Grosskreutz J J Neuroimmunol; 2014 May; 270(1-2):29-36. PubMed ID: 24666819 [TBL] [Abstract][Full Text] [Related]
8. An enhanced integrated stress response ameliorates mutant SOD1-induced ALS. Wang L; Popko B; Roos RP Hum Mol Genet; 2014 May; 23(10):2629-38. PubMed ID: 24368417 [TBL] [Abstract][Full Text] [Related]
9. Superoxide dismutase 1 mutants related to amyotrophic lateral sclerosis induce endoplasmic stress in neuro2a cells. Oh YK; Shin KS; Yuan J; Kang SJ J Neurochem; 2008 Feb; 104(4):993-1005. PubMed ID: 18233996 [TBL] [Abstract][Full Text] [Related]
10. Guanabenz inhibits TLR9 signaling through a pathway that is independent of eIF2α dephosphorylation by the GADD34/PP1c complex. Perego J; Mendes A; Bourbon C; Camosseto V; Combes A; Liu H; Manh TV; Dalet A; Chasson L; Spinelli L; Bardin N; Chiche L; Santos MAS; Gatti E; Pierre P Sci Signal; 2018 Jan; 11(514):. PubMed ID: 29363586 [TBL] [Abstract][Full Text] [Related]
11. Fine tuning of the unfolded protein response by ISRIB improves neuronal survival in a model of amyotrophic lateral sclerosis. Bugallo R; Marlin E; Baltanás A; Toledo E; Ferrero R; Vinueza-Gavilanes R; Larrea L; Arrasate M; Aragón T Cell Death Dis; 2020 May; 11(5):397. PubMed ID: 32457286 [TBL] [Abstract][Full Text] [Related]
13. Overexpression of human mutated G93A SOD1 changes dynamics of the ER mitochondria calcium cycle specifically in mouse embryonic motor neurons. Lautenschläger J; Prell T; Ruhmer J; Weidemann L; Witte OW; Grosskreutz J Exp Neurol; 2013 Sep; 247():91-100. PubMed ID: 23578819 [TBL] [Abstract][Full Text] [Related]
14. PERK modulation, with GSK2606414, Sephin1 or salubrinal, failed to produce therapeutic benefits in the SOD1G93A mouse model of ALS. Vieira FG; Tassinari VR; Kidd JD; Moreno A; Thompson K; Perrin S; Gill A; Hatzipetros T PLoS One; 2024; 19(2):e0292190. PubMed ID: 38359044 [TBL] [Abstract][Full Text] [Related]
15. Knocking down metabotropic glutamate receptor 1 improves survival and disease progression in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Milanese M; Giribaldi F; Melone M; Bonifacino T; Musante I; Carminati E; Rossi PI; Vergani L; Voci A; Conti F; Puliti A; Bonanno G Neurobiol Dis; 2014 Apr; 64():48-59. PubMed ID: 24361555 [TBL] [Abstract][Full Text] [Related]
16. Transcriptomic indices of fast and slow disease progression in two mouse models of amyotrophic lateral sclerosis. Nardo G; Iennaco R; Fusi N; Heath PR; Marino M; Trolese MC; Ferraiuolo L; Lawrence N; Shaw PJ; Bendotti C Brain; 2013 Nov; 136(Pt 11):3305-32. PubMed ID: 24065725 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of GADD34, the stress-inducible regulatory subunit of the endoplasmic reticulum stress response, does not enhance functional recovery after spinal cord injury. Ohri SS; Mullins A; Hetman M; Whittemore SR PLoS One; 2014; 9(11):e109703. PubMed ID: 25386686 [TBL] [Abstract][Full Text] [Related]
18. Increased ER stress during motor neuron degeneration in a transgenic mouse model of amyotrophic lateral sclerosis. Nagata T; Ilieva H; Murakami T; Shiote M; Narai H; Ohta Y; Hayashi T; Shoji M; Abe K Neurol Res; 2007 Dec; 29(8):767-71. PubMed ID: 17672929 [TBL] [Abstract][Full Text] [Related]
19. Neuroprotective effects of the Sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation. Peviani M; Salvaneschi E; Bontempi L; Petese A; Manzo A; Rossi D; Salmona M; Collina S; Bigini P; Curti D Neurobiol Dis; 2014 Feb; 62():218-32. PubMed ID: 24141020 [TBL] [Abstract][Full Text] [Related]
20. Guanabenz promotes neuronal survival via enhancement of ATF4 and parkin expression in models of Parkinson disease. Sun X; Aimé P; Dai D; Ramalingam N; Crary JF; Burke RE; Greene LA; Levy OA Exp Neurol; 2018 May; 303():95-107. PubMed ID: 29432724 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]